Home » Stocks » Medicenna Therapeutics

Medicenna Therapeutics Corp. (MDNA)

Stock Price: $4.16 USD 0.11 (2.72%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $4.25 +0.09 (2.16%) Oct 23, 5:04 PM

Stock Price Chart

Key Info

Market Cap 203.20M
Revenue (ttm) n/a
Net Income (ttm) -9.33M
Shares Out 48.85M
EPS (ttm) -0.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $4.16
Previous Close $4.05
Change ($) 0.11
Change (%) 2.72%
Day's Open 4.09
Day's Range 4.07 - 4.23
Day's Volume 71,109
52-Week Range 3.47 - 5.03

More Stats

Market Cap 203.20M
Enterprise Value 162.63M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 48.85M
Float 32.54M
EPS (basic) n/a
EPS (diluted) -0.19
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 29,639
Short Ratio 0.66
Short % of Float 0.09%
Beta 0.78
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.59
Revenue n/a
Operating Income n/a
Net Income -9.33M
Free Cash Flow n/a
Net Cash 40.57M
Net Cash / Share 0.83
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -26.63%
ROE -45.37%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(105.05% upside)
Current: $4.16
Target: 8.53
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-8.24-4.73
Net Income-8.28-4.71
Shares Outstanding31.9025.67
Earnings Per Share-0.26-0.18
Operating Cash Flow-8.95-8.04
Capital Expenditures--0.35
Free Cash Flow-8.95-8.39
Cash & Equivalents37.702.37
Total Debt0.07-
Net Cash / Debt37.632.37
Book Value36.152.62
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Medicenna Therapeutics Corp.
Country Canada
Employees 7
CEO Fahar Merchant

Stock Information

Ticker Symbol MDNA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MDNA


Medicenna Therapeutics, a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.